---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-012921"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:36:55.231649+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Applied DNA exits DNA tagging business, cuts 20% headcount; Q1 revenue $1.2M (+34% YoY), net loss $2.7M

## Summary
- Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.
- Exiting DNA Tagging segment; workforce reduction 20% (13% annual payroll cut); ~$300k severance in Q2 FY25.
- GMP Site 1 completed Jan 31, 2025, ISO 7/5 certified; projected annual revenue $10M-$30M at full capacity.
- Cash $9.3M as of Dec 31, 2024, includes $5.7M net from October registered direct offering.
- First-in-human clinical validation of Linea DNA in CAR-T therapy under Czech regulatory approval.

## SEC filing metadata
- accession: 0001104659-25-012921
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/0001104659-25-012921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465925012921/tm256524d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-012921
- JSON: https://secwatch.observer/filing/0001104659-25-012921.json
- Plain text: https://secwatch.observer/filing/0001104659-25-012921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.